'Indian private investors extremely risk averse'

Dr Radha Rangarajan is the co-founder of Vitas Pharma, a Hyderabad-based start-up incubated at Technology Business Incubator (TBI), University of Hyderabad (UoH) and IKP Knowledge Park, Hyderabad.


Dr Radha Rangarajan, co-founder, Vitas Pharma

She received her Bachelor's degree from Stanford University and PhD from Rockefeller University. She was a postdoctoral fellow at the Harvard School of Public Health in Infectious diseases.

Prior to Vitas, Dr Rangarajan was a scientist in the drug discovery division of Dr Reddy's Laboratories.

In her exclusive interview to BioSpectrum's Raj Gunashekar, she emphasizes that, as of now, Vitas' focus will mainly be on infectious diseases. She adds that for an entrepreneur, it is important to have clarity before establishing an enterprise.

In the field of new drug discovery for antibiotics, there are only a handful of companies worldwide. Dr Radha quotes this as Vitas Pharma's USP. She observes that in the West, investment in Biotechnology is considered as an essential component of growth.

With its operations kick-starting in 2011, Vitas Pharma is a drug discovery and development company, involved in identifying and developing next-generation antibiotics to treat multi-drug resistant hospital acquired infections.


Previous 1 3 4 5 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email